AR100262A1 - TREATMENT OF CROHN'S DISEASE WITH 6-DELAYED DELIVERY MERCAPTOPURINE - Google Patents

TREATMENT OF CROHN'S DISEASE WITH 6-DELAYED DELIVERY MERCAPTOPURINE

Info

Publication number
AR100262A1
AR100262A1 ARP150101330A ARP150101330A AR100262A1 AR 100262 A1 AR100262 A1 AR 100262A1 AR P150101330 A ARP150101330 A AR P150101330A AR P150101330 A ARP150101330 A AR P150101330A AR 100262 A1 AR100262 A1 AR 100262A1
Authority
AR
Argentina
Prior art keywords
mercaptopurine
crohn
disease
treatment
delayed
Prior art date
Application number
ARP150101330A
Other languages
Spanish (es)
Inventor
Kolarch Brenda
Hotovely-Salomon Anna
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR100262A1 publication Critical patent/AR100262A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos de tratamiento de pacientes que sufren de la enfermedad de Crohn o de colitis ulcerosa que no experimentaron una respuesta clínica a la administración anterior de tiopurina, o que sufrieron efectos secundarios debidos a la administración anterior de tiopurina, que comprenden administrar una composición farmacéutica de liberación demorada que comprende 6-mercaptopurina. Se divulgan asimismo métodos de tratamiento de pacientes que sufren de la enfermedad de Crohn o de colitis ulcerosa, a quienes también se les administra un esteroide, ácido 5-aminsalicílico o un antibiótico, que comprenden administrar de manera conjunta una composición farmacéutica de liberación demorada que comprende 6-mercaptopurina.Methods of treatment of patients suffering from Crohn's disease or ulcerative colitis who did not experience a clinical response to the previous administration of thiopurine, or who suffered side effects due to the previous administration of thiopurine, comprising administering a pharmaceutical release composition delayed comprising 6-mercaptopurine. Methods of treatment of patients suffering from Crohn's disease or ulcerative colitis, who are also administered a steroid, 5-aminalicylic acid or an antibiotic, which together administer a delayed-release pharmaceutical composition, are also disclosed. It comprises 6-mercaptopurine.

ARP150101330A 2014-05-02 2015-04-30 TREATMENT OF CROHN'S DISEASE WITH 6-DELAYED DELIVERY MERCAPTOPURINE AR100262A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461988068P 2014-05-02 2014-05-02

Publications (1)

Publication Number Publication Date
AR100262A1 true AR100262A1 (en) 2016-09-21

Family

ID=58700036

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101330A AR100262A1 (en) 2014-05-02 2015-04-30 TREATMENT OF CROHN'S DISEASE WITH 6-DELAYED DELIVERY MERCAPTOPURINE

Country Status (1)

Country Link
AR (1) AR100262A1 (en)

Similar Documents

Publication Publication Date Title
NI201700032A (en) USE OF A LONG-ACTING GLP-1 / GLUCAGON RECEPTOR DUAL AGONIST FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
JP2015057451A5 (en)
MX2016014346A (en) Treatment of crohn's disease with delayed-release 6-mercaptopurine.
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
CA3011103A1 (en) Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
BR112017027843A2 (en) pharmaceutical formulations comprising tenofovir and emtricitabine
MX2016011333A (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine.
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
EA201791067A1 (en) METHODS OF TREATING SUBJECTS WITH PRADER-WILLYE SYNDROME OR SMITH-MAGENIS SYNDROME
EA201792591A1 (en) PHARMACEUTICAL PREPARATIONS
MD20150120A2 (en) Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
PE20181332A1 (en) METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE
MX2017015664A (en) Intravenous administration of citrulline during surgery.
MX2017014776A (en) Pharmaceutical combination of everolimus with dactolisib.
MY193963A (en) Composition for treating joint diseases and kit containing same
AR099299A1 (en) INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
AR100262A1 (en) TREATMENT OF CROHN'S DISEASE WITH 6-DELAYED DELIVERY MERCAPTOPURINE
MX2018011293A (en) Prolonged release pharmaceutical composition comprising cysteamine or salt thereof.
MX2016006375A (en) A combination of dosage units for use in the treatment of pre-term labour condition.
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
Wang Benzathine benzylpenicillin/penicillins
EA201790089A1 (en) PHARMACEUTICAL MEANS FOR THE TREATMENT OF THE HEAD OF VARIOUS ETIOLOGY
Martinelli Neutropenia: case report
WO2016115442A3 (en) Therapeutic protein formulations
MD4458B1 (en) Use of Polybiolin drug in patients with liver cirrhosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure